As the relevance of LRRC8A or LRRC8D function for Pt drug uptake is independent of BRCA1/2 status, we also studied LRRC8A/D in patients with HNSCC, for which cisplatin is a standard therapy in combination with radiotherapy….Low LRRC8A gene expression correlated significantly with poor OS in these patients (P = 0.0057; Fig. 5C)....LRRC8D gene expression subgroups revealed decreased OS (P = 0.051) and poor tumor progression outcome (P = 0.054) in the low expression group....Hence, in cisplatin-treated patients with HNSCC, low LRRC8A and LRRC8D expression is associated with poor outcome.